Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease
Abstract
BACKGROUND: Recent trials have demonstrated better outcomes with intensive than with moderate statin treatment. Intensive treatment produced greater reductions in both low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP), suggesting a relationship between these two biomarkers and disease progression. METHODS: We performed intravascular ultrasonography in 502 patients with angiographically documented coronary disease. Patients were randomly assigned to receive moderate treatment (40 mg of pravastatin orally per day) or intensive treatment (80 mg of atorvastatin orally per day). Ultrasonography was repeated after 18 months to measure the progression of atherosclerosis. Lipoprotein and CRP levels were measured at baseline and follow-up. RESULTS: In the group as a whole, the mean LDL cholesterol level was reduced from 150.2 mg per deciliter (3.88 mmol per liter) at baseline to 94.5 mg per deciliter (2.44 mmol per liter) at 18 months (P<0.001), and the geometric mean CRP level decreased from 2.9 to 2.3 mg per liter (P<0.001). The correlation between the reduction in LDL cholesterol levels and that in CRP levels was weak but significant in the group as a whole (r=0.13, P=0.005), but not in either treatment group alone. In univariate analyses, the percent change in the levels of LDL cholesterol, CRP, apolipoprotein B-100, and non-high-density lipoprotein cholesterol were related to the rate of progression of atherosclerosis. After adjustment for the reduction in these lipid levels, the decrease in CRP levels was independently and significantly correlated with the rate of progression. Patients with reductions in both LDL cholesterol and CRP that were greater than the median had significantly slower rates of progression than patients with reductions in both biomarkers that were less than the median (P=0.001). CONCLUSIONS: For patients with coronary artery disease, the reduced rate of progression of atherosclerosis associated with intensive statin treatment, as compared with moderate statin treatment, is significantly related to greater reductions in the levels of both atherogenic lipoproteins and CRP.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Pharmacological therapies, including lipid-lowering and antihypertensive medications, are efficacious in lowering some of these risk factors, typically reducing cardiovascular disease risk by 20% to 30%.
“Pharmacological therapies, including lipidlowering and antihypertensive medications, are efficacious in lowering some of these risk factors, 2,3 typically reducing cardiovascular disease risk by 20% to 30%.2,4”
Cites
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439 · see citing works
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850 · see citing works
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938 · see citing works
Applied Linear Regression Models
(1997) · Technometrics · doi:10.1080/00401706.1997.10485142 · Cited by 4,638 · see citing works
Sever, P., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,756 · see citing works
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604 · see citing works
Clinical application of C-reactive protein for cardiovascular disease detection and prevention
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000053730.47739.3c · Cited by 2,513 · see citing works
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Brown, B. G., Ganz, P., Vogel, R. A., Crowe, T., Howard, G., Cooper, C. J., Brodie, B. R., et al. (2004) · JAMA · doi:10.1001/jama.291.9.1071 · Cited by 2,358 · see citing works
Self-citationGraphical Methods for Data Analysis.
Healy, M. J. R., Chambers, J. M., Cleveland, W. S., Kleiner, B., & Tukey, P. A. (1984) · Journal of the Royal Statistical Society Series A (General) · doi:10.2307/2981587 · Cited by 2,315 · see citing works
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292 · see citing works
Mintz, G. S., Nissen, S. E., Anderson, W. D., Bailey, S. R., Erbel, R. M., Fitzgerald, P. J., Pinto, F. J., Rosenfield, K., Siegel, R. J., Tuzcu, E. M., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01175-5 · Cited by 2,186 · see citing works
Self-citationNissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707 · see citing works
Self-citationEffect of Statin Therapy on C-Reactive Protein Levels
Albert, M. A., Danielson, E., Rifai, N., Ridker, P. M., & for the PRINCE Investigators (2001) · JAMA · doi:10.1001/jama.286.1.64 · Cited by 1,642 · see citing works
Eisen, H. J., Tuzcu, E. M., Dorent, R., KOBASHIGAWA, J. A., MANCINI, D. M., Valantine, H. A., Starling, R. C., Sørensen, K. E., Hummel, M. W., Lind, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022171 · Cited by 1,195 · see citing works
Self-citationVerma, S., Wang, C., Li, S., Dumont, A. S., Fedak, P. W. M., Badiwala, M. V., Dhillon, B., Weisel, R. D., Li, R., Mickle, D. A. G., et al. (2002) · Circulation · doi:10.1161/01.cir.0000029802.88087.5e · Cited by 1,052 · see citing works
Nissen, S. E., & Yock, P. G. (2001) · Circulation · doi:10.1161/01.cir.103.4.604 · Cited by 842 · see citing works
Self-citationC-reactive protein induces human peripheral blood monocytes to synthesize tissue factor
Čermák, J., Key, N., Bach, R., Balla, J., Jacob, H., & Vercellotti, G. (1993) · Blood · doi:10.1182/blood.v82.2.513.513 · Cited by 838 · see citing works
C-Reactive Protein in the Arterial Intima
Torzewski, M., Rist, C., Mortensen, R. F., Zwaka, T. P., Bienek, M., Waltenberger, J. L., Köenig, W., Schmitz, G., Hombach, V., & Torzewski, J. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.9.2094 · Cited by 581 · see citing works
Ridker, P. M., Rifai, N., Rose, L. M., Buring, J. E., & Cook, N. R. (2003) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000058687.18516.14 · Cited by 390 · see citing works
Isoprenoids as mediators of the biological effects of statins
Liao, J. K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216421 · Cited by 352 · see citing works
Simvastatin Lowers C-Reactive Protein Within 14 Days
Plenge, J. K., Hernandez, T. L., Weil, K. M., Poirier, P., Grunwald, G. K., Marcovina, S. M., & Eckel, R. H. (2002) · Circulation · doi:10.1161/01.cir.0000029743.68247.31 · Cited by 351 · see citing works
Elevated Serum C-Reactive Protein Levels and Early Arterial Changes in Healthy Children
Järvisalo, M. J., Harmoinen, A. P. T., Hakanen, M., Paakkunainen, U., Viikari, J. S. A., Hartiala, J., Lehtimäki, T. J., Simell, O., & Raitakari, O. T. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000024222.06463.21 · Cited by 315 · see citing works
Intensive Statin Therapy — A Sea Change in Cardiovascular Prevention
Topol, E. J. (2004) · New England Journal of Medicine · doi:10.1056/nejme048061 · Cited by 197 · see citing works
Zouki, C., Beauchamp, M., Baron, C., & Filep, J. G. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119561 · Cited by 152 · see citing works
High-Intensity Statin Treatment for Coronary Heart Disease
Sacks, F. M. (2004) · JAMA · doi:10.1001/jama.291.9.1132 · Cited by 84 · see citing works
Schoenhagen, P., Sapp, S. K., Tuzcu, E. M., Magyar, W. A., Popovich, J., Boumitri, M., Vince, D. G., Crowe, T., & Nissen, S. E. (2003) · Journal of the American Society of Echocardiography · doi:10.1067/mje.2003.45 · Cited by 53 · see citing works
Self-citationKent, S. M., & Taylor, A. J. (2003) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.07.040 · Cited by 18 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482 · see citing works
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773 · see citing works
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292 · see citing works
Nissen, S. E., Nicholls, S. J., Sipahi, I., Libby, P., Raichlen, J. S., Ballantyne, C. M., Davignon, J., Erbel, R., Fruchart, J. C., Tardif, J.-C., et al. (2006) · JAMA · doi:10.1001/jama.295.13.jpc60002 · Cited by 2,047 · see citing works
Self-citationThe intestinal microbiota fuelling metabolic inflammation
Tilg, H., Zmora, N., Adolph, T. E., & Elinav, E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0198-4 · Cited by 1,089 · see citing works
Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., Chaitman, B., Fromer, M., Gregoratos, G., Klein, G., Moss, A. J., Myerburg, R. J., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.178233 · Cited by 1,080 · see citing works
Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60447-5 · Cited by 1,010 · see citing works
Ridker, P. M. (2016) · Circulation Research · doi:10.1161/circresaha.115.306656 · Cited by 1,002 · see citing works
NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis
Grebe, A., Hoss, F., & Latz, E. (2018) · Circulation Research · doi:10.1161/circresaha.118.311362 · Cited by 926 · see citing works
Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction
Packard, R. R. S., & Libby, P. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.097360 · Cited by 925 · see citing works
Nissen, S. E., Nicholls, S. J., Wolski, K., Nesto, R., Kupfer, S., Perez, A., Jure, H., De Larochellière, R., Staniloae, C. S., Mavromatis, K., et al. (2008) · JAMA · doi:10.1001/jama.299.13.1561 · Cited by 850 · see citing works
Self-citationRidker, P. M., Thuren, T., Zalewski, A., & Libby, P. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.06.012 · Cited by 799 · see citing works
Ridker, P. M., Rifai, N., Cook, N. R., Bradwin, G., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.3.326 · Cited by 744 · see citing works
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis
Nicholls, S. J., Tuzcu, E. M., Sipahi, I., Grasso, A. W., Schoenhagen, P., Hu, T., Wolski, K., Crowe, T., Desai, M. Y., Hazen, S. L., et al. (2007) · JAMA · doi:10.1001/jama.297.5.499 · Cited by 724 · see citing works
Self-citationBalducci, S., Zanuso, S., Nicolucci, A., Fernando, F., Cavallo, S., Cardelli, P., Fallucca, S., Alessi, E., Letizia, C., Jimenez, A., et al. (2010) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.04.015 · Cited by 566 · see citing works
A systematic review and economic evaluation of statins for the prevention of coronary events
Ward, S., Lloyd Jones, M., Pandor, A., Holmes, M., Ara, R., Ryan, A., Yeo, W., & Payne, N. (2007) · Health Technology Assessment · doi:10.3310/hta11140 · Cited by 556 · see citing works
Ridker, P. M., Howard, C. P., Walter, V., Everett, B., Libby, P., Hensen, J., & Thuren, T. (2012) · Circulation · doi:10.1161/circulationaha.112.122556 · Cited by 530 · see citing works
New developments and novel therapeutic perspectives for vitamin C
Li, Y., & Schellhorn, H. E. (2007) · The Journal of Nutrition · doi:10.1093/jn/137.10.2171 · Cited by 508 · see citing works
The effect of including C-reactive protein in cardiovascular risk prediction models for women
Cook, N. R., Buring, J. E., & Ridker, P. M. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-1-200607040-00128 · Cited by 504 · see citing works
Inflammatory processes in cardiovascular disease: a route to targeted therapies
Ruparelia, N., Chai, J. T., Fisher, E. A., & Choudhury, R. P. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.185 · Cited by 477 · see citing works
Chiuve, S. E., McCullough, M. L., Sacks, F. M., & Rimm, E. B. (2006) · Circulation · doi:10.1161/circulationaha.106.621417 · Cited by 477 · see citing works
Ridker, P. M. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.11.037 · Cited by 414 · see citing works
Koushki, K., Shahbaz, S. K., Mashayekhi, K., Sadeghi, M., Zayeri, Z. D., Taba, M. Y., Banach, M., Al-Rasadi, K., Johnston, T. P., & Sahebkar, A. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08791-9 · Cited by 382 · see citing works
Ganz, P., Heidecker, B., Hveem, K., Jonasson, C., Kato, S., Segal, M. R., Sterling, D. G., & Williams, S. A. (2016) · JAMA · doi:10.1001/jama.2016.5951 · Cited by 364 · see citing works
Self-citationEarly and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes
Ray, K. K., Cannon, C. P., McCabe, C. H., Cairns, R., Tonkin, A. M., Sacks, F. M., Jackson, G., & Braunwald, E. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.03.077 · Cited by 356 · see citing works
Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study
Kaplan, H., Thompson, R. C., Trumble, B. C., Wann, L. S., Allam, A. H., Beheim, B., Frohlich, B., Sutherland, M. L., Sutherland, J. D., Stieglitz, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30752-3 · Cited by 338 · see citing works
Savoia, C., & Schiffrin, E. L. (2007) · Clinical Science · doi:10.1042/cs20060247 · Cited by 326 · see citing works
Koenig, W. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.113 · Cited by 315 · see citing works
LDL cholesterol: controversies and future therapeutic directions
Ridker, P. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61009-6 · Cited by 274 · see citing works
Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy
Pradhan, A. D., Aday, A. W., Rose, L. M., & Ridker, P. M. (2018) · Circulation · doi:10.1161/circulationaha.118.034645 · Cited by 258 · see citing works
Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis
Ridker, P. M. (2019) · Circulation Research · doi:10.1161/circresaha.118.313129 · Cited by 260 · see citing works
Davidson, M. H., Ballantyne, C. M., Jacobson, T. A., Bittner, V. A., Braun, L. T., Brown, A. S., Brown, W. V., Cromwell, W. C., Goldberg, R. B., McKenney, J. M., et al. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.07.005 · Cited by 262 · see citing works
Naruszewicz, M., Łaniewska, I., Millo, B., & Dłużniewski, M. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.12.032 · Cited by 262 · see citing works
Arnaud, C., Burger, F., Steffens, S., Veillard, N. R., Nguyen, T. H., Trono, D., & Mach, F. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000163840.63685.0c · Cited by 247 · see citing works
Gender-specific care of the patient with diabetes: review and recommendations
Legato, M. J., Gelzer, A., Goland, R., Ebner, S. A., Rajan, S., Villagra, V., & Kosowski, M. (2006) · Gender Medicine · doi:10.1016/s1550-8579(06)80202-0 · Cited by 225 · see citing works
Ridker, P. M. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.119214 · Cited by 206 · see citing works
Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects.
Yasuda, H., Yuen, P. S. T., Hu, X., Zhou, H., & Star, R. A. (2006) · Kidney International · doi:10.1038/sj.ki.5000300 · Cited by 209 · see citing works
Avan, A., Tavakoly Sany, S. B., Ghayour‐Mobarhan, M., Rahimi, H. R., Tajfard, M., & Ferns, G. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26791 · Cited by 182 · see citing works
Katsuki, S., Matoba, T., Nakashiro, S., Sato, K., Koga, J.-I., Nakano, K., Nakano, Y., Egusa, S., Sunagawa, K., & Egashira, K. (2014) · Circulation · doi:10.1161/circulationaha.113.002870 · Cited by 179 · see citing works
The Biological Role of Inflammation in Atherosclerosis
Wong, B. W., Meredith, A., Lin, D., & McManus, B. M. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.06.023 · Cited by 168 · see citing works
Clinical implications for statin pleiotropy
Liao, J. K. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000191913.16321.60 · Cited by 139 · see citing works
Ioannidou, E., Malekzadeh, T., & Dongari‐Bagtzoglou, A. (2006) · Journal of Periodontology · doi:10.1902/jop.2006.050443 · Cited by 118 · see citing works
Modeling Social Influences on Human Health
Karelina, K., & DeVries, A. C. (2011) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3182002116 · Cited by 115 · see citing works
Small LDL-Cholesterol is Superior to LDL-Cholesterol for Determining Severe Coronary Atherosclerosis
Koba, S., Yokota, Y., Hirano, T., Ito, Y., Ban, Y., Tsunoda, F., Sato, T., Shoji, M., Suzuki, H., Geshi, E., et al. (2008) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e572 · Cited by 102 · see citing works
Elimination of Neoangiogenesis for Plaque Stabilization
Kolodgie, F. D., Narula, J., Yuan, C., Burke, A. P., Finn, A. V., & Virmani, R. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.083 · Cited by 96 · see citing works
Guler, N., Batyraliev, T., Dulger, H., Ozkara, C., Tuncer, M., Aslan, S., Okut, H., & Agirbasli, M. (2006) · International Journal of Cardiology · doi:10.1016/j.ijcard.2005.06.027 · Cited by 33 · see citing works
- Authors
- Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Crowe, T., Sasiela, W. J., Tsai, J., Orazem, J., Magorien, R. D., O'Shaughnessy, C., & Ganz, P.
- Affiliations
- Cleveland Clinic (US)
- Pfizer (United States) (US)
- The Ohio State University Wexner Medical Center (US)
- Brigham and Women's Hospital (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-01-06
- Volume
- 352
- Issue
- 1
- Pages
- 29-38
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2102899779
- Cited by
- 1,325
- References
- 30
- Citations by year
- 2026: 13 · 2025: 19 · 2024: 25 · 2023: 26 · 2022: 35 · 2021: 39 · 2020: 44 · 2019: 38 · 2018: 38 · 2017: 29 · 2016: 37 · 2015: 42 · 2014: 58 · 2013: 53 · 2012: 49
- FWCI
- 169.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Keywords
- statin therapy, LDL cholesterol, C-reactive protein, coronary artery disease, atherosclerosis progression, atorvastatin, pravastatin, apolipoprotein B-100, non-HDL cholesterol, intravascular ultrasound, atherogenic lipoproteins
- MeSH terms
- Atorvastatin, Anticholesteremic Agents, C-Reactive Protein, Coronary Artery Disease, Coronary Vessels, Female, Heptanoic Acids, Humans, Lipids, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Pyrroles, Regression Analysis, Risk Factors, Biomarkers, Pravastatin, Ultrasonography, Interventional, Disease Progression, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
